Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory prospective study of hepatitis B virus kinetics during the first 24 weeks of telbivudine treatment
2007-003360-22Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of telbivudine in Chronic Hepatitis B (CHB) (2 cohorts), sponsored by Novartis. Primary endpoint: Reduction in HBV DNA level during 24 weeks of treatment. Started Oct 2007; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2007-003360-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003360-22.